| Code | CSB-RA015007MB3HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to obinutuzumab, targeting MS4A1 (CD20), a transmembrane phosphoprotein exclusively expressed on the surface of B lymphocytes from pre-B to mature B cell stages. MS4A1 plays a critical role in regulating B cell activation, proliferation, and differentiation through modulation of calcium influx and cell cycle progression. This target is centrally implicated in B cell malignancies including chronic lymphocytic leukemia, follicular lymphoma, and non-Hodgkin lymphomas, as well as autoimmune disorders characterized by aberrant B cell activity such as rheumatoid arthritis and multiple sclerosis.
Obinutuzumab is a glycoengineered type II anti-CD20 therapeutic antibody that demonstrates enhanced direct cell death induction and antibody-dependent cellular cytotoxicity compared to earlier type I anti-CD20 antibodies. This biosimilar provides researchers with a cost-effective tool for investigating B cell depletion mechanisms, evaluating therapeutic resistance pathways, and developing novel immunotherapeutic strategies for hematological malignancies and autoimmune diseases.
There are currently no reviews for this product.